Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1C | Q13936 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2840208 | 0.88 | CACNA1C (0.56) | CACNA1C | |
| SCHEMBL14773312 | 0.88 | CACNA1C (0.56) | CACNA1C | |
| SCHEMBL12318620 | 0.88 | CACNA1C (0.62) | CACNA1C | |
| SCHEMBL2402562 | 0.87 | CACNA1C (0.55) | CACNA1C | |
| SCHEMBL12337749 | 0.87 | CACNA1C (0.55) | CACNA1C | |
| SCHEMBL2401259 | 0.87 | CACNA1C (0.61) | CACNA1C | |
| SCHEMBL2843904 | 0.86 | CACNA1C (0.54) | CACNA1C | |
| SCHEMBL15940511 | 0.86 | CYP3A4 (0.59) | CACNA1C | |
| SCHEMBL12318990 | 0.86 | CACNA1C (0.60) | CACNA1C | |
| SCHEMBL12318906 | 0.85 | CACNA1C (0.60) | CACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2753618-B1 | HETEROCYCLIC-SUBSTITUED BENZOFURAN DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME (US) | 2018-04-11 | — | — | EP | disclosed |
| US-9549917-B2 | Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9549917-B2 | Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2017-01-24 | — | — | US | disclosed |
| US-9549917-B2 | Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases | MERCK SHARP & DOHME CORP. (US) | 2017-01-24 | — | — | US | disclosed |
| US-20140199263-A1 | HETEROCYCLIC-SUBSTITUTED BENZOFURAN DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC | 2014-07-17 | — | — | US | disclosed |
| US-20140199263-A1 | HETEROCYCLIC-SUBSTITUTED BENZOFURAN DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC | 2014-07-17 | — | — | US | disclosed |
| US-20140199263-A1 | HETEROCYCLIC-SUBSTITUTED BENZOFURAN DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME LLC | 2014-07-17 | — | — | US | disclosed |
| WO-2013034047-A1 | HETEROCYCLIC-SUBSTITUED BENZOFURAN DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013034047-A1 | HETEROCYCLIC-SUBSTITUED BENZOFURAN DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | MERCK SHARP & DOHME CORP. (US) | 2013-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140199263-A1 | HETEROCYCLIC-SUBSTITUTED BENZOFURAN DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES | HCCS, GTF3C5, EIF5B | CACNA1C 4397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.